YellowGrade
Biotech Rally Sparked by Alzheimer's Drug Has Staying Power

June 13, 2021, 9:03 a.m.

(The Wall Street Journal) Controversy surrounding Biogen’s Aduhelm could ignite political firestorm over high drug prices, but investors should look past any D.C. drama.

Login to grade this article.